Why TrueBlue Shares Are Diving Today

TrueBlue Inc (NYSE: TBI) shares are trading lower by over 18% after the company reported 

TrueBlue Inc (NYSE:TBI) shares are trading lower by over 18% after the company reported worse-than-expected Q2 FY23 financial results.

The company reported a revenue decline of 16% Y/Y to $476 million, missing the consensus of $496.1 million.

By segment, revenues declined by 13% Y/Y in PeopleReady, 33% Y/Y in PeopleScout, and 13% Y/Y in PeopleManagement business.

Adjusted EPS of $0.17 came below the consensus of $0.22.

As of Jun 25, 2023, cash and cash equivalents stood at $49.7 million, and operating cash flow came in at $20.9 million. 

“Our results reflect an environment of softening demand. Given the tight labor market, clients continue to focus on retaining employees, but they are also increasingly focused on reducing costs. As a result, clients are becoming more selective on which jobs they choose to fill….We maintained pricing discipline in our staffing segments and took additional actions to reduce costs,” said Taryn Owen, President & COO.

Outlook: For Q3 2023, the company expects revenue of $484 million-$509 million (vs. consensus of $516.88 million).

Also ReadBouncing Back Like a True Blue: Analyst Sees Upswing in Staffing Star’s Fortunes

Price Action: TBI shares are down by 18.5% at $14.89 on the last check Tuesday.

Total
0
Shares
Related Posts
Read More

Summit Therapeutics Ivonescimab In Combination with Chemotherapy Approved In China By NMPA For 2L+ EGFRm NSCLC Based On HARMONi-A Clinical Trial; Clinically Meaningful Efficacy Observed In Overall Survival Towards Ivonescimab Plus Chemotherapy; Shares…

 Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46For Subset of Patients Previously Receiving 3rd Generation

SMMT